Thursday, February 25, 2021
| 7:30 - 8:45am | SS1. Industry Supported CME Satellite Symposium* Rethinking Routines in Multiple Sclerosis Management: What the Future Holds for DMTs and Cognitive Assessment Strategies This CME activity is provided by CME Outfitters, LLC. This independent Industry Supported Satellite Symposium is supported by an educational grant from Bristol-Myers Squibb Company. |
|
| 8:45am - 9:00am | BREAK | |
| 9:00 - 10:00am | KJ1. Opening Address & Kenneth P. Johnson Memorial Lecture Chairs: Jeffrey A. Cohen, Cleveland Clinic and Anne Cross, Washington University in St. Louis Lecturer: Benjamin M. Segal, The Ohio State University |
|
| 10:00 - 10:45am | BA1. National Multiple Sclerosis Society (NMSS) Barancik Award Presentation and Talk | |
| 10:45 - 11:00am | BREAK | |
| 11:00am - 12:30pm | S1. Session 1 - Emerging Concepts in MS Chairs: Pavan Bhargava, Johns Hopkins University Theme: Highlighting cutting-edge studies that inform our understanding of the pathogenic mechanisms in MS, introduce novel measures to capture disease activity, and advance treatment options for affected individuals. This session will be comprised of six platform presentations by Young Investigators selected from submitted abstracts. |
|
| 11:00-11:05am | Introduction | |
| 11:05-11:15am | S1.1 Associations of Serum Neurofilament Light Chain with Clinical and Radiological Measures in a Large Real World MS Population Elias Sotirchos, Johns Hopkins University |
|
| 11:15 - 11:25am | S1.2 Role of MCAM+ Regulatory T Cells in Multiple Sclerosis Jennifer Sebali, Centre de Recherche du Centre Hospitalier de l'Université de Montréal |
|
| 11:25 - 11:35am | S1.3 Low Sun Exposure is a Risk Factor for Pediatric-Onset Multiple Sclerosis Prince Sebastian, Australian National University |
|
| 11:35 - 11:45am | S1.4 Adult-Onset Genetic Leukodystrophies Misdiagnosed as Multiple Sclerosis in Clinical Practice Alise Carlson, Cleveland Clinic |
|
| 11:45 - 11:55am | S1.5 Characteristics and Predictors of Disease Course in Children Initially Presenting with ADEM Alice Rutatangwa, University of California, San Francisco |
|
| 11:55 - 12:05pm | S1.6 Single Cell and Spatial RNA Sequencing Identify Candidates that Drive Aging-Exacerbated Neurodegeneration in the Spinal Cord Yifei Dong, University of Calgary |
|
| 12:05 - 12:30pm | Q&A Discussion | |
| 12:30 - 12:45pm | BREAK | |
| 12:45 - 2:15pm | S2. Session 2 - The Spectrum of MS Across the Lifespan Chairs: Riley Bove, University of California, San Francisco Rose-Marie Rébillard, Université de Montréal
Theme: This session examines the effects of extremes in age on MS, and the effects of aging on the CNS recovery capacity.Learning Objectives: 1) To define the effects of MS on cognition in pediatric-age MS patients; 2)To examine how aging and menopause alter remyelination and recovery from MS disease activity |
|
| 12:45 - 12:50pm | Introduction | |
| 12:50 - 1:05pm | S2.1 Pediatric Onset-Effects on Cognition and Long-Term Learning Lauren Krupp, NYU Langone Health |
|
| 1:05 - 1:20pm | S2.2 Aging and Rejuvenation of Oligodendrocytes Tal Iram, Stanford University |
|
| 1:20 - 1:35pm | S2.3 Effects of Aging on MS Jennifer Graves, University of California, San Diego |
|
| 1:35 - 1:50pm | S2.4 Menopause and Hormonal Effects Rhonda Voskuhl, University of California, Los Angeles |
|
| 1:50 - 2:15pm | Q&A Discussion | |
| 2:15 - 2:30pm | BREAK | |
|
2:30 - 3:45pm |
SS2. Industry Supported CME Satellite Symposium* The Rise of B Cell Therapies in Relapsing MS: Examining the State of the Science, New Therapeutic Options, and Patient-Centered Clinical Decision-Making This CME activity is jointly provided by PeerView Institute for Medical Education (PVI) and the Medical Learning Institute, Inc. This independent Industry Supported Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation. |
|
| 3:45 - 4:15pm | Brain Exchange Group Discussions: Disparities in Care in MS and Long-Term Safety Data | |
Friday, February 26, 2021
| 8:00 - 9:15am | SS3. Industry Supported CME Satellite Symposium* Upgrading the Standard of Care for Neuromyelitis Optica Spectrum Disorder (NMOSD): Novel Therapies This CME activity is provided by Med Learning Group. This independent Industry Supported Satellite Symposium is supported by an educational grant from Genentech, A Member of the Roche Group. |
||
| 9:15 - 9:45am | Brain Exchange Group Discussions: COVID-19 & MS and Recognizing & Managing Early Disease Progression in MS |
||
| 9:45 - 10:00am | BREAK | ||
| 10:00 - 11:30am | S3. Session 3 - LACTRIMS - The Spectrum of MS in the Hispanic and Latino Populations Chairs: Daniel Ontaneda, Cleveland Clinic Fernando Hamuy, Universidad Nacional de Asunción Theme: This session will focus on the manner in which MS affects Hispanic and Latino populations in the Caribbean, Central and South America. Learning Objectives: 1) To examine the demographic and clinical spectrum of MS in Hispanic and Latino populations; 2) To learn about the impact of obesity and the microbiome on MS in Hispanic/Latino population |
||
| 10:00 - 10:05am | Introduction | ||
| 10:05 - 10:20am | S3.1 The Reality of MS Epidemiology in LATAM Victor Rivera, Baylor College of Medicine |
||
| 10:20 - 10:35pm | S3.2 The Relationship Between Obesity and MS Metabolic-Immunological Interaction Jorge Correale, Raúl Carrea Institute for Neurological Research (FLENI), Argentina |
||
| 10:35 - 10:50am | S3.3 Spectrum of MS Demographics in LATAM Population Fernando Gracia, ULACIT University, Panama |
||
| 10:50 - 11:05pm | S3.4 MS and Intestinal Microbiota in LATAM Population Viviana Orozco, University of Puerto Rico, Medical Sciences Campus |
||
| 11:05 - 11:30am | Q&A Discussion | ||
| 11:30 - 11:45am | BREAK | ||
| 11:45am - 1:30pm | CE1. Cutting Edge Developments Chairs: Scott Zamvil, University of California, San Francisco Jo Anne Stratton, McGill University
Theme: This session will be comprised of two presentations from invited speakers followed by five groundbreaking platform presentations selected from submitted abstracts.Learning Objectives: 1) To learn about effects of MS and DMTs on COVID-19 development and recovery; 2) To examine what is known regarding effects of DMTs on response to vaccinations; 3) To learn about new research developments in MS considered to be "groundbreaking". |
||
| 11:45 - 11:50am | Introduction | ||
| 11:50am - 12:05pm | CE1.1 COVID-19 and MS-Registry Information Amber Salter, Washington University in St. Louis |
||
| 12:05 - 12:20pm | CE1.2 Vaccination Responses in Setting of Different Types of MS DMTs Amit Bar-Or, University of Pennsylvania |
||
| 12:20 - 12:30pm | CE1.4 Patterns of Disease-Modifying Treatment Use and Sociodemographic Characteristics in Multiple Sclerosis by Race and Ethnicity Carlos Pérez, The University of Texas Health Science Center at Houston |
||
| 12:30 - 12:40pm | CE1.5 Human Oligodendrocyte Lineage and Functional States Revealed by Single-Cell RNA Sequencing Analysis Julia Luo, McGill University |
||
| 12:40 - 12:50pm | CE1.6 Adenosine 2A Receptor Expression in Progressive MS is Associated with Astroglial Pan-activation and High Oxidative Toxicity Chih Lo, Yale University |
||
| 12:50 - 1:00pm | CE1.7 Quantification of Meningeal Enhancing Volume Reveals Relationships with Clinical Outcomes and Cortical Thinning on 7T MRI in MS Claire Allen, University of Maryland |
||
| 1:00 - 1:30pm | Q&A Discussion | ||
| 1:30 - 1:45pm | BREAK | ||
| 1:45 - 2:15pm | Brain Exchange Group Discussions: Sequencing of Medication and NMOSD | ||
| 2:15 - 2:45pm | Poster Session 1 - Imaging | ||
| 2:45 - 3:15pm | Poster Session 2 - Biomarkers/Central Vein Sign | ||
| 3:15 - 3:30pm | BREAK | ||
| 3:30 - 4:00pm | Poster Session 3 - Basic Science | ||
| 4:00 - 4:30pm | Poster Session 4 - Clinical | ||
Saturday, February 27, 2021
| 7:30 - 8:45am | SS4. Industry Supported CME Satellite Symposium* Addressing Healthcare Disparities and COVID-19 Concerns For All Patients with Multiple Sclerosis This CME activity is provided by AcademicCME. This independent Industry Supported Satellite Symposium is supported by educational grants from Biogen, Bristol-Myers Squibb Company and Sanofi Genzyme. |
|
| 8:45 - 9:00am | BREAK | |
| 9:00 - 10:30am | S4. Session 4 - The Spectrum of Inflammation and Environmental Impacts on Inflammation Chairs: Ruth Ann Marrie, University of Manitoba Lindsey Wooliscroft, Oregon Health Science University Theme: This session will focus on the impact of different environmental factors on inflammation and pathophysiology in relation to MS. Learning Objectives: 1) To learn about inflammasomes and pyroptosis in relation to MS; 2) To examine nutritional and metabolic factors that impact MS pathophysiology |
|
| 9:00 - 9:05am | Introduction | |
| 9:05 - 9:20am | S4.1 Inflammasomes and Pyroptosis in MS Chris Power, University of Alberta |
|
| 9:20 - 9:35am | S4.2 Mechanisms of Inflammation – Vitamin D Effects on Myeloid Cells Luke Healy, McGill University |
|
| 9:35 - 9:50am | S4.3 Weight, Obesity and Adipokines Laura Piccio, Washington University in St. Louis |
|
| 9:50 - 10:05am | S4.4 Impact of Methionine Intake on Inflammation Catherine Larochelle, Université de Montréal |
|
| 10:05 - 10:30am | Q&A Discussion | |
| 10:30 - 10:45am | BREAK | |
| 10:45am - 12:15pm | S5. Session 5 - The Spectrum of Other Non-MS Inflammatory CNS Diseases Chairs: Anastasia Zekeridou, Mayo Clinic Dalia Rotstein, University of Toronto
Theme: This session will focus on non-MS CNS inflammatory and autoimmune disorders. Learning Objectives: 1) To learn the latest regarding the pathophysiology underlying neuromyelitis optica and its treatment; 2) To learn about CNS inflammatory disorders due to checkpoint inhibitor therapy; 3) To be updated on the spectrum of autoimmune encephalitides |
|
| 10:45 - 10:50am | Introduction | |
| 10:50 - 11:05am | S5.1 Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica Jeffrey Bennett, University of Colorado |
|
| 11:05 - 11:20am | S5.2 NMO and Anti-MOG: Updates on Diagnosis and Treatment Sean J. Pittock, Mayo Clinic |
|
| 11:20 - 11:35am | S5.3 CNS Inflammatory Complications of Check-point Inhibitors Matt Schindler, Penn Medicine |
|
| 11:35am - 11:50pm | S5.4 Autoimmune Encephalitis Divyanshu Dubey, MBBS Mayo |
|
| 11:50am - 12:15pm | Q&A Discussion | |
| 12:15-12:30pm | BREAK | |
| 12:30-1:00pm | Brain Exchange Group Discussions: MS Care & Research in Women Across the Lifespan and MOG Antibody Disease | |
| 1:00 - 2:30pm | S6. Session 6 - The Spectrum of Disease Severity: From Benign to Aggressive MS Chairs: Fred Lublin, Mt. Sinai NYC Erin Longbrake, Yale University
Learning Objectives: 1) To understand the differences between benign and aggressive MS clinically and based on imaging; 2) To examine the role of the innate immune system in progressive MS; 3) To learn about the subset of MS in which cognition is primarily affectedTheme: This session will focus on current understanding of MS subtypes of differing disease aggressiveness. |
|
| 1:00 - 1:05pm | Introduction | |
| 1:05 - 1:20pm | S6.1 The Innate Immune System in Progressive MS V. Wee Yong, University of Calgary |
|
| 1:20 - 1:35pm | S6.2 Spectrum of Imaging Findings in Benign vs. Aggressive MS Robert Naismith, Washington University at St. Louis |
|
| 1:35 - 1:50pm | S6.3 Cerebral/Cognitive-Predominant MS Claire Riley, Columbia University |
|
| 1:50 - 2:05pm | S6.4 Benign MS and Aggressive MS – Nature or Nurture? Mark Freedman, University of Ottawa |
|
| 2:05 - 2:30pm | Q&A Discussion | |
| 2:30 - 2:45pm | Closing Remarks Jeffrey A. Cohen, Cleveland Clinic |
|
On-Demand Symposia
On-Demand Symposia will be made available at 6:30 am CT on Thursday, February 25.
- AP1. European Charcot Foundation Symposium: Silent Progression - Does it Exist?
- AP2. IMSVISUAL Symposium
- AP3. iWiMS Session: Meet iWiMS
- AP4. NAIMS Symposium: Big Data and Machine Learning with MRI in Multiple Sclerosis
*Independent Industry Supported CME Satellite Symposia are not included in the ACTRIMS Forum 2021 accredited program.